

# Preclinical Imaging Market to Exhibit a Valuation of US\$ 3,011.7 Million By 2031 | Top 10 Players Hold 90.9% Revenue

CHICAGO, UNITED STATES, July 17, 2023

/EINPresswire.com/ -- The global [preclinical imaging market](#) is estimated to witness a rise in revenue and reach **US\$ 3,011.7 million** by 2031, growing at a **CAGR of 10.1%** during the forecast period from 2023 to 2031. In 2022, the market generated a revenue of **US\$ 2,450.0 million**.

For more information, contact [astute@astuteanalytica.com](mailto:astute@astuteanalytica.com) or visit <https://www.astuteanalytica.com/request-sample/preclinical-imaging-market>

The global preclinical imaging market has great potential owing to the growing demand for non-invasive imaging techniques for drug development, illness diagnostics, and research. The market has been steadily growing, and this trend will continue. Growth in the market is also due to technological developments and the appearance of new imaging modalities like molecular imaging and optical imaging.

A fast-growing multidiscipline, molecular imaging integrates molecular biology, chemistry, computer science, engineering, and medicine. It is capable of real-time, non-invasive viewing and quantification of physiological or pathological processes occurring at the cellular or molecular level in a living organism. Multimodal molecular imaging may soon provide presymptomatic detection, targeted therapy, and personalized medicine due to the rapid advancement of technology. Since typical MRI equipment is more expensive, complex, and technically demanding, Aspect Imaging created the M2 platform and a suite of tools that allow researchers to take advantage of the power and quantitative insights of MRI for small animal phenotyping and drug discovery.

The usage of in-vivo imaging systems in preclinical research is growing due to the rising number of Clinical Research Organizations (CROs) and pharmaceutical companies, which is likely to accelerate the growth of the preclinical imaging market. For instance, in June 2020, the USF Health Morsani College of Medicine will install new 7T-3T MR/PET and PET-CT systems with MR



solutions to create their first thorough preclinical imaging suite.

Astute Analytica forecasts that the market will expand as more pharmaceutical companies use image-based drug discovery and development methodologies. Preclinical imagers will be able to offer even more insights into the mechanisms underlying disease and prospective treatment targets due to the introduction of new technologies like artificial intelligence (AI) and machine learning. For instance, in May 2023, the NCI funded the use of AI to enhance breast cancer treatment. The Centers for Disease Control and Prevention (CDC) estimate that around 264,000 women and 2,400 men are diagnosed with breast cancer in the United States each year. RPI and Albany Medical College are continuing their long-standing collaboration to find out how AI may help with the treatment of breast cancer after securing US\$ 3.3 in funding from the NCI.

Preclinical imaging is a critical technology used by pharmaceutical companies when creating new drugs and therapies. It allows one to observe how biological processes work in living things, providing crucial information on efficiency and security. The demand for preclinical imaging services has significantly increased in recent years as more organizations seek to gain a competitive edge in drug development.

The ultrasonic imaging segment is likely to dominate the market with a market share of over 25%. This is because ultrasonic imaging is non-invasive, economical, and capable of providing real-time images. The preclinical imaging market uses ultrasound imaging extensively for research and development, particularly in the fields of developmental biology, cancer research, and cardiovascular research. This segment will continue growing as high-frequency ultrasound imaging and 3D ultrasound imaging technologies become more widely used.

Preclinical imaging is a crucial technology used by pharmaceutical companies when creating new drugs and therapies. It allows one to observe how biological processes work in living things, providing crucial information on efficiency and security. The demand for preclinical imaging services has significantly increased in recent years as more organizations seek to gain a competitive edge in drug development.

The pharmaceutical companies captured more than 33% of the total revenue. Preclinical imaging is a crucial technology used by pharmaceutical companies when creating new drugs and therapies. It allows one to observe how biological processes work in living things, providing crucial information on efficiency and security. The demand for preclinical imaging services has significantly increased in recent years as more organizations seek to gain a competitive edge in drug development.

The market is expanding owing to the biotech companies' increasing R&D expenditures, particularly in the fields of drug development and discovery. The early stages of drug research, which are the emphasis of biotech companies, require preclinical imaging. These businesses are working to develop novel drugs and therapies for several diseases and problems.

Preclinical imaging is a crucial technology used by pharmaceutical companies when creating new drugs and therapies. It allows one to observe how biological processes work in living things, providing crucial information on efficiency and security. The demand for preclinical imaging services has significantly increased in recent years as more organizations seek to gain a competitive edge in drug development.

Due to a number of factors, including the region's high need for improved imaging technologies, the prevalence of chronic diseases, and increased funding in preclinical research, North America is likely to hold a revenue share of over 44% in the preclinical imaging market, followed by

Europe with a revenue share of over 29%.

European Commission has proposed a new rule that would make it easier for small businesses to get finance. As a result, this might promote more innovation in the sector. In addition, many of the largest companies in the market are investing heavily in research and development in the hopes of creating new products that will support a recovery in sales.

For more information, visit <https://www.astuteanalytica.com/industry-report/preclinical-imaging-market>

The market is highly fragmented and competitive. Market players are involved in implementing strategic initiatives, such as product upgrades, regional expansions, portfolio diversification, and mergers and acquisition. According to Astute Analytica analysis, the top 10 players include General Electric (GE), Siemens Healthineers, Canon, Fujifilm Corporation, Hitachi, Ltd., Konica Minolta, Inc., Varex Imaging, Hologic, etc., collectively dominate the global market. In addition, Siemens Healthineers and General Electric (GE) are the market leaders capturing 23.50% and 21.60%.

Siemens Healthineers is the world's foremost provider of medical technology. X-ray computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are all among the preclinical imaging services and products the company provides. Siemens Healthineers also offers software options for data management and picture analysis.

Another significant company in the preclinical imaging sector is General Electric. The CT, MRI, PET/SPECT, ultrasound, and X-ray products and services provided by GE Healthcare are extensive. Additionally, the business offers customer support for the whole product life cycle, including purchase, installation, maintenance, and repair.

The following table lists the top 10 players in the preclinical imaging market:

Top 10 Players in the Preclinical Imaging Market

- Agilent Technologies
- Bruker Corporation
- Canon
- Fujifilm Corporation
- General Electric (GE)
- Hitachi, Ltd.
- Hologic
- Konica Minolta, Inc.
- Koninklijke Philips
- Mediso Limited
- MILabs B.V.

- Molecubes
- MR Solutions
- PerkinElmer, Incorporated
- Siemens Healthineers
- TriFoil Imaging
- Varex Imaging
- Other Prominent Players

□□□□□□□□□□ □□□□□□

□□□ □□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□ □□ □□□□, □□□□□□□□, □□□□□□□□□□□□, □□□-□□□□, □□□□□□□□□□□□ □□□□□□□□, □□□ □□□□□□□.

□□ □□□□

- Products
  - o Instruments
  - o Reagents
  - o Software Tools
- Imaging Services

□□ □□□□□□□

- CT Imaging
- Optical Imaging
- Ultrasound Imaging
- MRI Imaging
- PET/SPECT Imaging
- Others

□□ □□□□□□□□□□

- Research and Development
- Drug Discovery

□□ □□□ □□□□

- Biotech Companies
- Research Institutes
- Pharmaceutical Companies

□□ □□□□□□□□□□□ □□□□□□□□

- Online
- Offline

□□ □□□□□□

- North America
  - o The U.S.
  - o Canada
  - o Mexico
- Europe

- Western Europe
  - The UK
  - Germany
  - France
  - Italy
  - Spain
- Rest of Western Europe
- Eastern Europe
  - Poland
  - Russia
- Rest of Eastern Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia & New Zealand
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East & Africa (MEA)
  - Saudi Arabia
  - South Africa
  - UAE
  - Rest of MEA
- South America
  - Argentina
  - Brazil
  - Rest of South America

□□□□□□□□ □□□□□□□□ □□□□□□ □□□□ □□ □□□□□□□□□□ □□□□□□@-  
<https://www.astuteanalytica.com/request-sample/preclinical-imaging-market>

□□□□□□ □□□□□□□□ □□□□□□□□□□:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while

surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg

Astute Analytica

+1 888-429-6757

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/644801868>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.